Monte Rosa Therapeutics, Inc. (GLUE) — SEC Filings
Monte Rosa Therapeutics, Inc. (GLUE) — 38 SEC filings. Latest: 8-K (May 7, 2026). Includes 14 8-K, 8 SC 13G/A, 6 10-Q.
View Monte Rosa Therapeutics, Inc. on SEC EDGAR
Overview
Monte Rosa Therapeutics, Inc. (GLUE) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Monte Rosa Therapeutics, Inc. (GLUE) reported a significant increase in collaboration revenue for the nine months ended September 30, 2025, reaching $120.891 million, a substantial rise from $14.975 million in the same period of 2024. This surge in revenue led to a net income of $7.509 million for t
Sentiment Summary
Across 38 filings, the sentiment breakdown is: 1 bullish, 35 neutral, 2 mixed. The dominant filing sentiment for Monte Rosa Therapeutics, Inc. is neutral.
Filing Type Overview
Monte Rosa Therapeutics, Inc. (GLUE) has filed 14 8-K, 6 10-Q, 1 DEF 14A, 2 10-K, 8 SC 13G/A, 5 SC 13D/A, 1 DEFA14A, 1 SC 13G with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (38)
Risk Profile
Risk Assessment: Of GLUE's 26 recent filings, 1 were flagged as high-risk, 14 as medium-risk, and 11 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $120.891M |
| Net Income | $7.509M |
| EPS | $0.09 |
| Debt-to-Equity | N/A |
| Cash Position | $391.3M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Dr. Alan L. Rabinowitz
- Dr. Jonathan E. Leipsic
- ALI BEHBAHANI
- ANTHONY A. FLORENCE, JR.
- CARMEN CHANG
- EDWARD T. MATHERS
- FOREST BASKETT
- MOHAMAD H. MAKHZOUMI
- Dr. Jonathan G. Hall
- Ms. Sarah E. Kelly
- Ali Behbahani
- Mohamad H. Makhzoumi
- Anthony A. Florence, Jr.
- Carmen Chang
- Edward T. Mathers
Industry Context
Monte Rosa Therapeutics operates in the highly competitive biotechnology sector, focusing on the development of novel small molecule precision medicines. The industry is characterized by significant investment in research and development, long product development cycles, and stringent regulatory hurdles. Companies like Monte Rosa are leveraging advanced technologies such as molecular glue degraders and proprietary discovery engines to address unmet medical needs.
Top Tags
financials (5) · sec-filing (5) · Biotechnology (4) · 10-Q (4) · biotech (4) · ownership-change (3) · amendment (3) · Drug Discovery (2) · Molecular Glue Degraders (2) · R&D Spending (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Collaboration Revenue | $120.891M | Increased from $14.975M in 9M 2024, driving nine-month profitability. |
| Net Income | $7.509M | For the nine months ended September 30, 2025, a significant turnaround from a $86.137M net loss in 9M 2024. |
| Net Loss | $27.081M | For the three months ended September 30, 2025, indicating ongoing operational losses in the quarter. |
| Research and Development Expenses | $99.521M | Increased from $82.697M in 9M 2024, reflecting continued investment in pipeline. |
| Cash and Cash Equivalents | $208.343M | As of September 30, 2025, down from $224.254M at December 31, 2024. |
| Marketable Securities | $182.915M | Increased from $147.895M at December 31, 2024, providing liquidity. |
| Current Deferred Revenue | $24.791M | Decreased significantly from $117.232M at December 31, 2024, due to revenue recognition. |
| Shares Outstanding | 61,790,239 | As of September 30, 2025, indicating slight dilution from 61,507,446 shares at December 31, 2024. |
| Basic Earnings Per Share | $0.09 | For the nine months ended September 30, 2025, a positive shift from $(1.21) in 9M 2024. |
| Accumulated Deficit | $431.079M | Reduced from $438.588M at December 31, 2024, due to the nine-month net income. |
| SEC File Number | 001-40522 | Identifies the company's filing history with the SEC. |
| IRS Employer Identification No. | 84-3766197 | Tax identification number for the company. |
| General and Administrative Expenses | $7.4M | for the three months ended June 30, 2025, stable from 2024 |
| Reporting Period End Date | 20250331 | Indicates the end of the financial quarter being reported. |
| Filing Date | 20250508 | Shows when the 10-Q was officially submitted to the SEC. |
Forward-Looking Statements
- {"claim":"FMR LLC will maintain a significant ownership stake in Monte Rosa Therapeutics for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Monte Rosa Therapeutics, Inc. (GLUE)?
Monte Rosa Therapeutics, Inc. has 38 recent SEC filings from Jan 2024 to May 2026, including 14 8-K, 8 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of GLUE filings?
Across 38 filings, the sentiment breakdown is: 1 bullish, 35 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Monte Rosa Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Monte Rosa Therapeutics, Inc. (GLUE) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Monte Rosa Therapeutics, Inc.?
Key financial highlights from Monte Rosa Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for GLUE?
The investment thesis for GLUE includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Monte Rosa Therapeutics, Inc.?
Key executives identified across Monte Rosa Therapeutics, Inc.'s filings include Dr. Alan L. Rabinowitz, Dr. Jonathan E. Leipsic, ALI BEHBAHANI, ANTHONY A. FLORENCE, JR., CARMEN CHANG and 15 others.
What are the main risk factors for Monte Rosa Therapeutics, Inc. stock?
Of GLUE's 26 assessed filings, 1 were flagged high-risk, 14 medium-risk, and 11 low-risk.
What are recent predictions and forward guidance from Monte Rosa Therapeutics, Inc.?
Recent forward-looking statements from Monte Rosa Therapeutics, Inc. include guidance on {"claim":"FMR LLC will maintain a significant ownership stake in Monte Rosa Therapeutics for the foreseeable future.","e.